Shanghai-based Zai Lab Limited is making waves in the pharmaceutical industry with its innovative therapies to treat a range of diseases including oncology, autoimmune disorders, infectious diseases, and neuroscience. The company's successful commercial products, such as Zejula, Optune, NUZYRA, and Qinlock, have been instrumental in providing effective treatment options to patients in Mainland China and Hong Kong. Additionally, Zai Lab is also developing promising new drugs such as Odronextamab, Repotrectinib, Margetuximab, Tisotumab vedotin, Adagrasib, and Bemarituzumab that target various cancers. Moreover, the company's pipeline includes a range of investigational drugs such as Zipalertinib, Elzovantinib, ZL-2313, ZL-1211, ZL-1218, Efgartigimod, ZL-1102, Sulbactam/durlobactam, and KarXT, which have the potential to transform the treatment landscape for psychiatric and neurological conditions. Despite being incorporated in 2013, Zai Lab has already established itself as a leading player in the healthcare sector and continues to innovate and push the envelope in drug development.
Zai Lab Limited's ticker is ZLAB
The company's shares trade on the NASDAQ stock exchange
They are based in Pudong, China
There are 501-1000 employees working at Zai Lab Limited
It is http://www.zailaboratory.com/index.aspx
Zai Lab Limited is in the Healthcare sector
Zai Lab Limited is in the Biotechnology industry
The following five companies are Zai Lab Limited's industry peers: